Purging metastases in lymphoid organs using a combination of antigen-nonspecific adoptive T cell therapy, oncolytic virotherapy and immunotherapy (original) (raw)

• Markovic, S.N. et al. Malignant melanoma in the 21st century, part 2: staging, prognosis and treatment. Mayo Clin. Proc. 82, 490–513 (2007).
  Article Google Scholar
• Chang, G.J., Rodriguez-Bigas, M.A., Skibber, J.M. & Moyer, V.A. Lymph node evaluation and survival after curative resection of colon cancer: systematic review. J. Natl. Cancer Inst. 99, 433–441 (2007).
  Article Google Scholar
• Benson, J.R., della Rovere, G.Q. & Group, A.M.C. Management of the axilla in women with breast cancer. Lancet Oncol. 8, 331–348 (2007).
  Article Google Scholar
• Beri, A. & Janetschek, G. Radioguided sentinel lymph node dissection in the staging of prostate cancer. Nat. Clin. Pract. Urol. 3, 602–610 (2006).
  Article Google Scholar
• Kim, R., Emi, M., Tanabe, K. & Arihiro, K. Immunobiology of the sentinel lymph node and its potential role for anti tumor immunity. Lancet Oncol. 7, 1006–1016 (2006).
  Article CAS Google Scholar
• Munn, D.H. & Mellor, A.L. The tumor draining lymph node as an immune privileged site. Immunol. Rev. 213, 146–158 (2006).
  Article Google Scholar
• Matsuura, K. et al. Maturation of dendritic cells and T cell responses in sentinel lymph nodes from patients with breast carcinoma. Cancer 106, 1227–1236 (2006).
  Article CAS Google Scholar
• Murta, E.F., Andrade, J.M., Falcao, R.P. & Bighetti, S. Lymphocyte subpopulations in patients with advanced breast cancer submitted to neoadjuvant chemotherapy. Tumori 86, 403–407 (2000).
  Article CAS Google Scholar
• Arnould, L. et al. Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? Br. J. Cancer 94, 259–267 (2006).
  Article CAS Google Scholar
• Walker, L.S.K. & Abbas, A.K. The enemy within: keeping self-reactive T cells at bay in the periphery. Nat. Rev. Immunol. 2, 11–19 (2002).
  Article CAS Google Scholar
• Thomas, D.A. & Massague, J. TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell 8, 369–380 (2005).
  Article CAS Google Scholar
• Harrington, K. et al. Cells as vehicles for cancer gene therapy: the missing link between targeted vectors and systemic delivery? Hum. Gene Ther. 13, 1263–1280 (2002).
  Article CAS Google Scholar
• Crittenden, M. et al. Pharmacologically regulated production of targeted retrovirus from T cells for systemic antitumor gene therapy. Cancer Res. 63, 3173–3180 (2003).
  CAS PubMed Google Scholar
• Chester, J. et al. Tumor antigen–specific induction of transcriptionally targeted retroviral vectors from chimeric immune receptor-modified T cells. Nat. Biotechnol. 20, 256–263 (2002).
  Article CAS Google Scholar
• Cole, C. et al. Tumor-targeted, systemic delivery of therapeutic viral vectors using hitchhiking on antigen-specific T cells. Nat. Med. 11, 1073–1081 (2005).
  Article CAS Google Scholar
• Kottke, T. et al. The perforin-dependent immunological synapse allows T-cell activation–dependent tumor targeting by MLV vector particles. Gene Ther. 13, 1166–1177 (2006).
  Article CAS Google Scholar
• Thanarajasingam, U. et al. Delivery of CCL-21 to metastatic disease improves the efficacy of adoptive T-cell therapy. Cancer Res. 67, 300–308 (2007).
  Article CAS Google Scholar
• Thorne, S.H., Bartlett, D.L. & Kirn, D.H. The use of oncolytic vaccinia viruses in the treatment of cancer: a new role for an old ally? Curr. Gene Ther. 5, 429–443 (2005).
  Article CAS Google Scholar
• Power, A.T. et al. Carrier cell–based delivery of an oncolytic virus circumvents antiviral immunity. Mol. Ther. 15, 123–130 (2007).
  Article CAS Google Scholar
• Ong, H.T., Hasegawa, K., Dietz, A.B., Russell, S.J. & Peng, K.W. Evaluation of T cells as carriers for systemic measles virotherapy in the presence of antiviral antibodies. Gene Ther. 14, 324–333 (2007).
  Article CAS Google Scholar
• Yotnda, P., Savoldo, B., Charlet-Berguerand, N., Rooney, C. & Brenner, M. Targeted delivery of adenoviral vectors by cytotoxic T cells. Blood 104, 2272–2280 (2004).
  Article CAS Google Scholar
• Morgan, R.A. et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314, 126–129 (2006).
  Article CAS Google Scholar
• Peters, A.M. The use of nuclear medicine in infections. Br. J. Radiol. 71, 252–261 (1998).
  Article CAS Google Scholar
• Shields, J.D. et al. Chemokine-mediated migration of melanoma cells towards lymphatics a mechanism contributing to metastasis. Oncogene 26, 2997–3005 (2007).
  Article CAS Google Scholar
• Takeuchi, H. et al. CCL21 chemokine regulates chemokine receptor CCR7 bearing malignant melanoma cells. Clin. Cancer Res. 10, 2351–2358 (2004).
  Article CAS Google Scholar
• Wiley, H.E., Gonzalez, E.B., Maki, W., Wu, M. & Hwang, S.T. Expression of CC chemokine receptor-7 and regional lymph node metastasis of B16 murine melanoma. J. Natl. Cancer Inst. 93, 1638–1643 (2001).
  Article CAS Google Scholar
• Weninger, W. & von Andrian, U.H. Chemokine regulation of naive T cell traffic in health and disease. Semin. Immunol. 15, 257–270 (2003).
  Article CAS Google Scholar
• Kelly, E. & Russell, S.J. History of oncolytic viruses: genesis to genetic engineering. Mol. Ther. 15, 211–219 (2007).
  Article CAS Google Scholar
• Stojdl, D.F. et al. VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 4, 263–275 (2003).
  Article CAS Google Scholar
• Fernandez, M., Porosnicu, M., Markovic, D. & Barber, G.N. Genetically engineered vesicular stomatitis virus in gene therapy: application for treatment of malignant disease. J. Virol. 76, 895–904 (2002).
  Article CAS Google Scholar
• Balachandran, S., Porosnicu, M. & Barber, G.N. Oncolytic activity of vesicular stomatitis virus is effective against tumors exhibiting aberrant p53, Ras, or myc function and involves the induction of apoptosis. J. Virol. 75, 3474–3479 (2001).
  Article CAS Google Scholar
• Balachandran, S. & Barber, G.N. Vesicular stomatitis virus therapy of tumors. IUBMB Life 50, 135–138 (2000).
  Article CAS Google Scholar
• Shinozaki, K., Ebert, O. & Woo, S.L. Eradication of advanced hepatocellular carcinoma in rats via repeated hepatic arterial infusions of recombinant VSV. Hepatology 41, 196–203 (2005).
  Article Google Scholar
• Ebert, O., Harbaran, S., Shinozaki, K. & Woo, S.L. Systemic therapy of experimental breast cancer metastases by mutant vesicular stomatitis virus in immune-competent mice. Cancer Gene Ther. 12, 350–358 (2005).
  Article CAS Google Scholar
• Stojdl, D.F. et al. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat. Med. 6, 821–825 (2000).
  Article CAS Google Scholar
• Lun, X. et al. Effects of intravenously administered recombinant vesicular stomatitis virus on multifocal and invasive gliomas. J. Natl. Cancer Inst. 98, 1546–1557 (2006).
  Article CAS Google Scholar
• Diaz, R.M. et al. Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus. Cancer Res. 67, 2840–2848 (2007).
  Article CAS Google Scholar
• Lichty, B.D. et al. Vesicular stomatitis virus: a potential therapeutic virus for the treatment of hematologic malignancy. Hum. Gene Ther. 15, 821–831 (2004).
  Article CAS Google Scholar
• Thirukkumaran, C.M., Russell, J.A., Stewart, D.A. & Morris, D.G. Viral purging of haematological autografts: should we sneeze on the graft? Bone Marrow Transplant. 40, 1–12 (2007).
  Article CAS Google Scholar
• Engelhorn, M.E. et al. Autoimmunity and tumor immunity induced by immune responses to mutations in self. Nat. Med. 12, 198–206 (2006).
  Article CAS Google Scholar
• Linardakis, E. et al. Enhancing the efficacy of a weak allogeneic melanoma vaccine by viral fusogenic membrane glycoprotein–mediated tumor cell–tumor cell fusion. Cancer Res. 62, 5495–5504 (2002).
  CAS Google Scholar
• Dyall, R. et al. Heteroclitic immunization induces tumor immunity. J. Exp. Med. 188, 1553–1561 (1998).
  Article CAS Google Scholar
• Hogquist, K.A. et al. T cell receptor antagonist peptides induce positive selection. Cell 76, 17–27 (1994).
  Article CAS Google Scholar
• Altman, D.G. Analysis of survival times. in Practical Statistics for Medical Research (Ed. Altman, D.G.) 365–395 (Chapman and Hall, London, 1991).
  Google Scholar